NCT03822078View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab (AMG 162) in Japanese Postmenopausal Women

PHASE1CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

December 24, 2004

Study Completion Date

December 24, 2004

Conditions
Osteoporosis
Interventions
DRUG

Placebo

Administered by subcutaneous injection

BIOLOGICAL

Denosumab

Administered by subcutaneous injection

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY